权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

The immune regulation of macrophage antibody dependent cellular phagocytosis

巨噬细胞抗体依赖性细胞吞噬作用的免疫调节

基本信息

批准号：
10397134
负责人：
Adam David Hoppe
金额：
$ 37.39万
依托单位：
SOUTH DAKOTA STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-07-10 至 2025-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10397134
关键词：
Actins Adoptive Transfer Agonist Antibodies Autoimmune Diseases B-Lymphocytes Binding Biological Assay Bone Marrow CCND1 gene CD47 gene CD8B1 gene CDW52 gene CRISPR screen Cells Clustered Regularly Interspaced Short Palindromic Repeats Complex Data Data Set Dependence Disease remission Environment Gene Expression Gene Expression Profiling Gene Expression Regulation Genes Genetic Transcription Goals Human IL4 gene Immune Immunocompetent Immunoglobulin G Immunologics Immunosuppression Infection Inflammatory Interferon Type II Interferons Intervention Knock-out Ligands Lymphocyte Lymphoma Macrophage Activation Malignant - descriptor Malignant Neoplasms Mediating Membrane Metabolic Methods Microscopy Mission Modeling Molecular Monoclonal Antibodies Monoclonal Antibody CD20 Monoclonal Antibody Therapy Mus Myeloid Cells PTPNS1 gene Pathway interactions Patients Peripheral Blood Mononuclear Cell Pharmacotherapy Public Health Receptor Signaling Regulation Regulatory T-Lymphocyte Signal Transduction Spleen Stimulator of Interferon Genes Surface System Systems Analysis Systems Biology T-Lymphocyte Testing Therapeutic Therapeutic Effect Therapeutic Monoclonal Antibodies Therapeutic antibodies Translating Translations United States National Institutes of Health Variant Work anti-CD20 antibody-dependent cellular phagocytosis base clinically relevant cytokine defined contribution design effective therapy gene function human tissue humanized mouse immune function immunoregulation improved in vivo in vivo Model inhibiting antibody innovation macrophage mouse model novel patient response programs receptor receptor expression receptor function response rituximab screening therapeutic target tissue repair transcriptome sequencing transcriptomics whole genome

项目摘要

Project Summary The killing of target cells by therapeutic antibodies is expanding the effective treatment options for a wide range of autoimmune diseases and cancers. Mounting evidence from mouse models, humanized mouse systems and the analysis of human tissues, indicates that macrophages are principal effectors of therapeutic antibodies, mediating the destruction of infected, malignant and immunologically aberrant cells. Fcγ receptors (FcR) on the surface of macrophages bind target-cell associated monoclonal IgG class antibodies (mAbs) to initiate antibody-dependent cellular phagocytosis (ADCP) and killing of the target cell. Patient responses to mAb therapies can vary from complete remission to minimal therapeutic effect. One poorly explored possibility is that the variability of the ADCP response is its dependence on macrophage polarization under the influence of immune modulation. Specifically, immunosuppressive environments alter macrophage polarization leading to ineffective ADCP. Conversely, stimulators of interferon genes agonists (STINGa), acting through type 1 interferons (IFN-1) can dramatically potentiate ADCP and overcome immunosuppression. Our overarching goal is to elucidate the mechanistic pathways by which macrophage activation controls FcR function and ADCP using a systems biology approach across in vivo transcriptomics and whole genome CRISPR screens. Identified gene-function relationships for ADCP will be validated in a novel vivo model and translated to human macrophages and therapeutic antibodies. We hypothesize that ADCP is regulated across major axes of macrophage polarization (M0, M1(IFNγ/LPS), M(IFN-1/STING), M2(IL4/13) and M(S)) by gene-expression changes of yet undefined genes that modulate the A:I ratios of FcRs, their signaling machinery and innate cellular recognition receptors. Our proposal has two innovative aims that will vastly expand understanding of the regulation FcR-dependent ADCP. In Aim 1, we will elucidate the macrophage genes contributing to differential FcR function and ADCP across M1, M(IFN-1/STING), M2 and M(S). This aim takes advantage of a new CRISPR-based whole genome screening strategy to identify genes that promote and inhibit ADCP in primary derived macrophages. Aim 2 will delineate macrophage gene regulation supporting FcR function and ADCP in vivo. Here we will translate findings from patient data and the CRISPR screen from Aim 1 to define regulators of ADCP in vivo. Both aims will focus on clinically relevant anti-B cell (Rituximab) and anti-T cell (CAMPATH) antibodies, and will generate findings that extend our understanding of Fc-dependent killing mechanism of ADCP.

项目总结